 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
DexCom, Inc. (DXCM) is a medical device company. The firm focuses on the design, development, and commercialization of continuous glucose monitoring systems.
The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes DexCom G4 system, a continuous glucose monitoring system; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring.
Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital.
The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. DexCom, Inc. markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States.
The firm is expected to report its quarterly results on Wednesday April 29th. The company has consistently exceeded expectations in the past. The current consensus estimates call for a loss of 11 cents per share. Ahead of the report, shares have formed a bullish "cup and handle." Note the 30-day moving average shown in red. We expect shares to see a pullback before heading higher. Use the weakness to establish a position!
52-Weeks Trading Range: $28.09 - $71.24
Entry Point: $65.90
Stop Loss: $62.60
Target Price: $72.49
We are taking profits on DXCM after its 30 days expired. Closed at $71.21. We believe this stock is heading higher!
